Abstract. In order to identify novel targets for the molecular therapy of gastric cancer (GC), we investigated the mRNA and protein expression of frizzled-2 (Fz2), a Wnt signaling pathway receptor. Reverse-transcriptase polymerase chain reaction (PCR) amplification was utilized to determine the expression patterns of Fz genes in normal stomach and in the GC cell lines MKN45 and MKN74. Immunostaining was performed on surgical specimens of GC using an antibody against Fz2. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay was performed on MKN45 cells and MKN74 cells transfected with Fz2 short-hairpin (sh) RNA. Cell motility was analyzed by scratch assay following Fz2 shRNA. Real-time quantitative PCR was performed to analyze the expression levels of cyclin D1 and matrix metallopeptidase 9 (MMP-9). Fz1, 3, 6 and 8 were expressed in normal stomach, and in MKN45 and MKN74 cells. Fz2 was expressed in normal stomach and in MKN45, but not in MKN74 cells. Well-differentiated GC tissue was weakly positive for Fz2 in cell membranes. Fz2 was positive in both the cell membrane and cytoplasm of GC tissues of moderately differentiated and poorly differentiated adenocarcinoma. Signet ring cells were positive for cytoplasmic Fz2. Proliferation of MKN45 and MKN74 cells was suppressed by Fz2 shRNA, and a scratch assay demonstrated that Fz2 shRNA suppressed also MKN45 and MKN74 cell motility. Furthermore, Fz2 shRNA application led to downregulated mRNA expression of both cyclin 3, 6 and 8 were expressed in normal stomach, and in MKN45 and MKN74 GC cells. Fz2 shRNA suppressed cell proliferation and motility of MKN45 and MKN74 cells, and downregulated cyclin D1 and MMP-9 expression in these GC cell lines.
Introduction
Gastric cancer (GC) accounts for 8% of total cases and 10% of total deaths from cancer worldwide (1) . Although the endoscopic approach has improved cancer diagnosis and treatment, especially of early GC, prognosis is still poor for advanced types (2, 3) . Consequently, the development of effective molecular therapies for GC is eagerly awaited.
The Wnt pathway is involved in cell proliferation and differentiation (4) . Wnt proteins bind to their receptor, frizzled (Fz), and its co-receptors, low-density lipoprotein receptor-related proteins 5 and 6 (LRP5/6), to form a complex (5, 6) . Once Wnt binds to its receptor complex, cytoplasmic β-catenin is accumulated through inhibition of its degradation by the glycogen synthase kinase (GSK)-3β complex (7) . β-catenin acts as a co-factor of the T-cell factor (TCF)/lymphoid enhancer factor (LEF) and activates target genes (8) . Activity of the Wnt pathway is also controlled by inhibition of secreted proteins such as dickkopf homolog-3 (9) . Constitutive activation of the Wnt pathway leads to abnormal cell growth and the development of GC (10, 11) .
Wnt5a is upregulated in GC possibly due to demethylation of its promoter (12) . The Fz3 and 6 receptors transduce the Wnt signal (13) . Furthermore, the expression level of β-catenin has been shown to be upregulated in the MKN-45 GC cell line (14) . Notably, upregulated β-catenin has been correlated with poor prognosis of patients with GC (14) , and methylation of dickkopf homolog 3 has also been associated with poor prognosis of GC (15) . Together, these reports clearly indicate that the Wnt pathway is activated in GC. It was, therefore, expected that inhibition of the Wnt pathway might be developed into a new molecular therapy for GC. In comparison, it has been shown that both downregulation of Fz2 and inhibitors of the Wnt pathway successfully suppress the proliferation of hepatocellular carcinoma and pancreatic cancer cells (16) (17) (18) (19) .
Therefore, we analyzed the effects of Fz2 inhibition using short hairpin RNA (shRNA) on the proliferation and motility of GC cell lines.
Materials and methods
This study was approved by the institutional ethics committee of the National Hospital Organization Shimoshizu Hospital, Table I . Real-time quantitative PCR was performed for 40 cycles with 5 sec denaturation at 95˚C and 5 sec annealing/extension at 60˚C. GAPDH and RPL19 were used as internal controls of RT-PCR and real-time quantitative PCR, respectively.
Immunostaining. Serial sections were cut from surgical samples, formalin-fixed, and embedded in paraffin (BioChain). The samples: well-differentiated adenocarcinoma (56-weekold female), moderately-differentiated adenocarcinoma (61-year-old female), poorly-differentiated adenocarcinoma (74-year-old male), and signet ring cells (62-year-old male) (BioChain) were deparaffinized, autoclaved, and incubated first with hydrogen peroxide, and then with 2% normal goat serum in phosphate-buffered saline (PbS) (washing buffer) for 30 min. After overnight incubation with a rabbit polyclonal anti-Fz2 antibody (1:5,000) (Sigma-Aldrich), specimens were rinsed with PbS and subsequently incubated with horseradish peroxidase-labeled anti-rabbit antibody (1:500) for 2 h (GE Healthcare, Pittsburgh PA, USA). Next, diaminobenzidine (Dako, Glostrup, Denmark) was applied to the tissue sections as a chromogen, and the nuclei were stained with hematoxylin (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) for 15 sec. Specimens were observed and photographed under an AX80 microscope (Olympus, Tokyo, Japan). 
Results
To analyze the expression patterns of Fz genes in normal stomach, and in MKN45 and MKN74 cells, RT-PCR was performed and the products subjected to electrophoresis (Fig. 1A) . Fz1, 3, 6 and 8 were expressed in normal stomach, and in MKN45 and MKN74 cell lines. Fz2 was expressed in normal stomach and in MKN45, but not in MKN74 cells. This result suggested that the expression of Fz2 varied between the cell lines. To determine the expression levels of Fz2 in normal stomach, and in MKN45 and MKN74 cell lines, real-time quantitative PCR was performed (Fig. 1b) . The relative expression levels of Fz2 in MKN45 and MKN74 lines were 1.94±0.85 and 0.48±0.11 (mean ± standard deviation), respectively, as compared with that in normal stomach. It was therefore confirmed that expression of Fz2 was dependent on the cell line analyzed.
To reveal the expression of Fz2 in GC tissues, surgical specimens were immunostained with an antibody for the Fz2 protein (Fig. 2) . Well-differentiated GC was weakly positive for Fz2 staining in the cell membranes ( Fig. 2A) . Fz2 staining was positive in both the cell membranes and the cytoplasm of GC tissues of moderately-differentiated and poorly-differentiated adenocarcinoma (Fig. 2b and C) . Signet ring cells showed positive cytoplasmic staining for Fz2 (Fig. 2D) . These results suggested that Fz2 was present in GC tissues, and that its expression levels are dependent on the grade of pathological differentiation.
To address the possibility that proliferation of GC cell lines might be suppressed with downregulation of Fz2, Fz2 shRNA was transfected into the GC MKN45 and MKN74 cell lines (Fig. 3) . Proliferation of the MKN45 cell line was suppressed to 53.2±23.4% of that of mock transfected cells (P<0.05) at 100 ng/well MTS (Fig. 3A) ; similarly, proliferation of MKN74 cells was suppressed to 59.9±38.2% (P<0.05) of that of mock transfected cells at 100 ng/well MTS (Fig. 3b) .
To confirm the downregulation of Fz2 by Fz2 shRNA, the expression levels of the Fz2 gene were quantitated. Expression levels of cyclin D1, involved in cell proliferation (20) , were also analyzed. Quantitative real-time PCR demonstrated that the expression levels of Fz2 and cyclin D1 in MKN45 cells were downregulated to 64.9±15.9% (P<0.05) and 56.7±6.6% (P<0.05) of mock-transfected cells, respectively, at 2.5 µg/well Fz2 shRNA (Fig. 4A and b) . In the MKN74 cell line, the expression levels of Fz2 and cyclin D1 were downregulated to 3.8±0.4% (P<0.05) and 3.7±0.8% (P<0.05) of those in mocktransfected cells, respectively, at 2.5 µg/well Fz2 shRNA ( Fig. 4C and D) .
To address the possibility that shRNA of Fz2 suppressed cell motility, a scratch assay was performed. Following transfection, the cell sheet was scratched and distance of migration was measured over a set time length (Fig. 5A-D) . Distance of migration was suppressed from 607±102 µm in mock transfected MKN45 cells to 261±47 µm (P<0.05) at 2.5 µg/well Fz2 shRNA (Fig. 5E) . Similarly, the distance of migration was suppressed from 209±43 µm in mock transfected MKN74 cells to 52±12 µm (P<0.05) at 2.5 µg/well Fz2 shRNA (Fig. 5F) .
To reveal the mechanism of suppression of cell motility, the expression levels of MMP9, a gene involved in cancer metastasis (21), were quantitated. MMP9 was downregulated to 20.4±3.6% (P<0.05) and 13.8±2.8% (P<0.05) in MKN45 and MKN74 cells transfected with at 2.5 µg Fz2 shRNA, respectively, as compared with mock transfections (Fig. 6A and b) .
Discussion
Expression patterns of Fz genes in normal stomach have not been reported (22) (23) (24) (25) (26) (27) (28) (29) . In our study, Fz1, 2, 3, 6 and 8 were shown to be expressed in normal stomach. It has previously been demonstrated that the GC cell lines MKN45 and MKN74 are positive for Fz3 expression using northern blot analysis (23) . In the present study, we also demonstrated that both cell lines were positive for Fz3 expression using RT-PCR. Our data showed that MKN45 and MKN74 cells were negative and positive for Fz4 and Fz6 expression, respectively, consistent with previous reports (24, 26) .
In contrast, the present data showed that Fz2 was upregulated in the MKN45 GC cell line, but downregulated in MKN74. Fz2 was chosen for further analysis to address the possibility that downregulation of Fz2 might suppress the proliferation and motility of MKN45 and MKN74 cells. MTS and scratch assays clearly showed that Fz2 shRNA successfully suppressed the proliferation and motility of both cell lines. These results indicated that Fz2 might be a novel target for the development of molecular therapies for GC. We also observed Fz2-mediated downregulation of cyclin D1, which is involved in cell proliferation (20) and is also downregulated by an inhibitor of the Wnt pathway (17) . These results and our data together suggested that Fz2 shRNA suppressed cell proliferation and motility via suppression of the Wnt pathway.
Our data clearly also demonstrated that MMP9, which has been established to be involved in cell motility (21) , was downregulated by Fz2 shRNA in GC cell lines, which also demonstrated suppression of cell motility. As the expression of MMP9 is associated with the expression of Wnt3a in human primary lung cancer tissues (30) , this, along with our results, suggested that MMP9 was a downstream target of the Wnt pathway.
One limitation of our study was that Fz2 was expressed in normal stomach. It was difficult to know what types of cells were positive for Fz1, 2, 3, 6 and 8. Stomach tissue is composed of mucous, muscle, and serous tissue, as well as nerves and blood vessels.
In conclusion, Fz2, 3, 6 and 8 were expressed in normal stomach, and in MKN45 and MKN74 GC cell lines. Fz2 shRNA suppressed cell proliferation and motility of MKN45 and MKN74 cells, and cyclin D1 and MMP9 expression was downregulated by Fz2 shRNA. Together, these results suggested that Fz2 might be a novel target for the development of molecular therapies for GC.
